Empower lists compounded sermorelin acetate injection through its 503A pharmacy catalog. The page identifies lyophilized, or dried, preparations in several strengths. Those details help identify a proposed prescription, but they do not establish the complete clinical service, a monthly cost, or the suitability of treatment.
Our review combines public product information with relevant FDA material checked on September 20, 2026. We did not purchase, test, or inspect medication. CoreAge Rx receives commercial placement on this site; that relationship does not turn this pharmacy comparison into evidence that another company’s preparation is better.
Verify the exact pharmacy, preparation, full cost, and current response to relevant public records. A catalog entry is not a quality certification or complete care plan.
What the injection listing actually offers
The reviewed catalog identifies lyophilized sermorelin acetate injection in 6 mg, 9 mg, and 15 mg strengths. These figures describe total ingredient amounts in the listed preparations. They are not a universal daily prescription and do not alone specify the concentration after preparation.
Ask which exact product the clinician intends to prescribe and what arrives in the shipment. A dried preparation raises different instruction questions from a ready-to-use liquid. The reconstitution guide explains what to verify with the pharmacy without supplying a generic mixing recipe. Do not infer that a larger vial is a better value until the pharmacy explains the prescribed supply duration and beyond-use conditions.
Keep the pharmacy separate from the prescriber
Empower's catalog is a pharmacy source. A clinic or online service may arrange an assessment and send a prescription, but that does not make every service fee an Empower pharmacy charge. Ask who makes the clinical decision, who dispenses the medicine, and who handles a refill or side-effect question.
If a provider says it uses Empower, confirm the dispensing entity for your specific order. A platform's pharmacy relationships can vary by product and location. The pharmacy and provider-types article is useful when a checkout brand and a vial label use different names. Neither name should leave you uncertain about whom to contact after delivery.
A relevant FDA warning letter needs context
FDA issued warning letter 700964 to Empower Clinic Services, LLC doing business as Empower Pharmacy on April 2, 2025. It concerned the Houston facility at 7601 N Sam Houston Parkway West following a September–October 2024 inspection. FDA described deficiencies involving sterile-drug production and insanitary conditions.
This is a material historical facility record. It is not a finding that every current sermorelin vial is contaminated, and we have not independently established the current corrective-action status. Ask the dispensing pharmacy how the record relates to your facility and what current documentation addresses the concerns. Do not infer either complete resolution or present batch failure from the existence of the letter alone.
Ask quality questions that identify the product
Begin with the pharmacy's legal name and location, then the preparation and lot information where provided. If the pharmacy supplies testing documents, ask whether they concern the raw ingredient, an intermediate preparation, or the finished product. Those are different objects of testing.
Ask how the pharmacy evaluates relevant quality attributes and how it handles complaints or potential recalls. A reader should not need to become a laboratory specialist, but the answer should be more specific than “high quality.” This review does not certify a lot, validate a certificate of analysis, or replace a current pharmacy-license check. Our pharmacy checklist explains the basic verification steps.
The missing price is a reason to request an itemized quote
The reviewed injection page did not provide a complete monthly patient price. Ask for the medication charge, quantity, supplies, shipping, and any preparation-related costs. If you are working through a clinic, obtain its assessment and follow-up fees too.
A price per vial is not directly comparable with a service's advertised monthly plan. Nor can a cost per milligram establish which treatment arrangement is better for you. The prescription and care needs come first. Use the cost guide to compare the same period and services, with separate entries for initial and repeat charges. Leave reimbursement out of the calculation until it has actually been confirmed.
Storage instructions must survive the handoff
If the clinician sends the prescription through another platform, make sure the pharmacy's instructions reach you with the medication. Confirm storage before and after preparation, the beyond-use date, and whom to call if something is unclear. Do not rely on an old screenshot from a previous vial or another brand.
Ask for help that fits your needs: readable print, a demonstration using the supplied equipment, or an explanation that you can repeat back. If a shipment is late or damaged, the pharmacy needs the delivery facts and product details to advise you. The shipping and temperature guide provides a practical record to keep.
The catalog’s evidence language is not an approval
Empower's page discusses the history of sermorelin and distinguishes unproven anti-aging use in healthy adults. That is a useful limitation to retain when a clinic markets the same ingredient more broadly. A reference to historical GEREF approval does not confer FDA approval on the present compounded preparation.
The important question is whether the proposed use has appropriate evidence for your circumstances. A clinician may need to investigate symptoms or an endocrine diagnosis instead of offering a wellness prescription. Our approval article and benefits guide explain why the history of an ingredient and the evidence for a current treatment are separate issues.
Our assessment of the available information
Empower's product-level details can help a patient clarify what a prescriber is ordering. The unresolved pieces are the patient-specific price, the complete clinical arrangement, and current answers about the relevant facility record. A useful review should preserve those gaps instead of replacing them with a star rating.
Read the Olympia review for another pharmacy model, or the CoreAge Rx review for an online service comparison. Apply the same questions to each: who treats you, what is dispensed, what you pay, and who responds when there is a concern. Choosing a provider should not depend on assuming that all products bearing the ingredient name are identical.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Empower Pharmacy: Sermorelin acetate injectionPrimary or authoritative reference · Pharmacy product page; not a complete care package or checkout quote.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
- HHS: Telehealth licensing across state linesUS government guidance · Licensure options depend on the patient location and state rules.
- FDA: Empower Pharmacy warning letter, April 2, 2025US regulator / historical enforcement record · Facility-specific warning letter following a 2024 inspection. Not a finding about every current sermorelin vial; current corrective-action status was not independently established.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- NABP: Buy medication safelyPharmacy regulator association · Tools for checking online pharmacies and recognizing unsafe sellers.
- FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
- IRS: Publication 502, Medical and Dental ExpensesUS tax authority · Medical-expense definitions; not an individual insurance or account-eligibility determination.
- FDA: Safe drug use after a natural disasterUS regulator · General temperature-exposure guidance. Does not establish a sermorelin stability window or injectable reconstitution method.
- Mayo Clinic: Sermorelin injection informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- FDA: 2013 GEREF withdrawal determinationFederal Register / FDA · Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.
- Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- Olympia Pharmacy: Compounded sermorelin injectionProvider primary source · Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.
- CoreAge Rx: Sermorelin product pageProvider primary source · Live product page; starting price is not a verified checkout total.